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We have analyzed the activity and regulated expression of a new Epstein-Barr virus (EBV) rrans-activator (I’ta) 
encoded by left reading frame 4 (BI’LF4) of the BarnHI I’fragment. The gene was detected in all genomes of established 
EBV strains and individual isolates, with the exception of 895-8, where the type-specific deletion of this open reading 
frame is tolerated in vitro. Specific rrans-activation of two EBV promoters (early MS and I’ta promoter) could be shown 
in cotransfection assays. The I’ta product affected autoactivation but had no influence on heterologous target pro- 
moters. The I’ta promoter segment was shown to be costimulated in the process of host cell differentiation in the 
absence of other EBV gene products. Expression of the reading frame in bacteria identified a 48-kDa protein as a stable 
gene product. I’ta-specific antibodies were detected in sera from EBV-positive persons (nasopharyngeal carcinoma). 
When expressed with suitable eucaryotic vectors, a nuclear protein could be immunostained in transfected cells. Our 
experiments suggest a cell type-specific requirement for I’ta in the lytic cycle of EBV at a determined differentiation 
stage of the host cell. D 1991 Academic Press, Inc. 
INTRODUCTION 
The Epstein-Barr virus (EBV), a human herpesvirus 
causing infectious mononucleosis as a primary dis- 
ease, is an ubiquitous pathogen. Lifelong persistence 
in B lymphocytes is under control of the immune sys 
tern; however, chronic active progression of an acute 
infection or of neoplasias, like Burkitt’s lymphoma or 
nasopharyngeal carcinoma, can develop in certain cir- 
cumstances (Wolf et al., 1987). Lymphoid cells are far 
from being the only site for EBV replication and a tis- 
sue-specific virus/host interaction is a central feature 
of EBV pathobiology (Wolf et al., 1984). At present, 
epithelial tissue appears to be a site of viral persistence 
and a source of virus production. Regulation of viral 
replication is dependent on the differentiation of its 
host cells (Becker et a/., 1989). EBV regulation is char- 
acterized by latency and the cascade of the lytic cycle 
of replication, comparable to several other herpesvirus 
systems, such as herpes simplex virus (Roizman and 
Batterson, 1985) or Herpesvirus saimiri (Hell et a/., 
1985). 
Lytic activation is based on the induction of trans-act- 
ing, nuclear proteins (Chevallier-Greco er a/., 1986; 
Countryman et a/., 1987; Hardwick eta/., 1988; Lieber- 
mann et a/., 1986; Marschall et a/., 1989a) belonging to 
the immediate early regulatory class (Biggin et a/., 
1987). RNA analysis by our group suggested an addi- 
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tional transcript, which appeared to be independent of 
prior synthesis of viral proteins and maps in the EBV 
BarnHI I’ section (Seibl et al., 1987). In this work we 
characterize the Epstein-Barr virus BI’LF4 trans-acti- 
vator, designated I’ta. Gene functions including pro- 
moter activity, protein synthesis in bacteria and cell 
systems, transacting properties, and autoregulation 
are described. We established a dynamic model sys- 
tem using a secreted reporter product to prove the 
transcriptional dependence of this gene on the pro- 
ceeding differentiation of the host cell. A specific differ- 
entiated stage emerges to play a key role in the lytic 
cycle of EBV. In epithelial cells, the I’ta gene was 
shown to be inducible and functional. In lymphoid 
cells, deletion of this lytic regulator seems to be tolera- 
ble under favorable conditions, but this deletion was 
shown to be rather exceptional in natural isolates. 
MATERIALS AND METHODS 
Plasmid constructions 
The coding sequence of the open reading frame 
(ORF) BI’LF4 was derived from cm 302-21 cosmid DNA 
(Polack et a/., 1984) using the restriction sites of SalI 
and BarnHI (1390-bp fragment). For the construction of 
pSVI’, regulatory elements of the simian virus 40 (SV40) 
(early promoter/enhancer as 830-bp Taql-Srul frag- 
ment and splice/polyadenylation signals as 1640-bp 
Ncol-Pstl fragment) were excised from the original 
0042-6822/91 $3.00 
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pSV2CAT construction (Gorman et a/., 1982). As 
shown in Fig. 1 B these fragments were inserted into 
plin vectors, derived from pUC by insertion of new syn- 
thetic polylinkers (Max von Pettenkofer-Institute, Mu- 
nich). In pSCI’, the TATA box of the SV40 early pro- 
moter was replaced by the human cytomegalovirus 
(HCMV) immediate early promoter/enhancer (Ncol- 
Sa/l insertion of the subcloned HCMV sequence as 
described below) to optimize expression. For bacterial 
protein synthesis, the ORF BI’LF4 was positioned 
under the control of either the hybrid trpllac promoter 
in vector pTrc99A (Amann et a/., 1988) (Fig. 1 B) or the 
combined phage T7 promoter (Al)//ac operator in vec- 
tor pUHE24-2 (Bujard et al., 1987). The I’ta promoter 
element, an 890-bp Alul-Alul fragment, subcloned 
from H3-Dl cosmid DNA (Polack et a/., 1984), was 
inserted into reporter gene constructs using the coding 
sequence for either CAT or HBsAg as a reporter ele- 
ment. Cloning strategies for all EBV promoter regions 
and reporter constructions were described in detail 
previously (Marschall et al., 198913). For controls, the 
HCMV immediate early promoter/enhancer (770-bp 
HindIll-Hpall fragment) (Boshat-t et a/., 1985) was sub- 
cloned into pUC18, cut by HindIll and Accl, and subse- 
quently inserted upstream from the reporter se- 
quences generating pCMVHBs and pCMVCAT. In the 
BZLFl expression vector pCMVZ (including two 
spliced exons at the 3’-end) (Manet et al., 1989) this 
HCMV element was used to promote transcription of 
the genomic BarnHI Z sequence (1065-bp Nael-Ncol 
fragment) (Skare et al., 1980). 
Cell culture, transfections, and induced 
differentiation 
HeLa, COS-1, and mouse teratocarcinoma F9 cells 
were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) fetal calf serum, 100 
units/ml of penicillin, and 250 Fg/ml of streptomycin. 
Eight hours before transfection, the cells were seeded 
at a density of lO?lOO-mm petri dish. The cells were 
transfected by the CaHPO, method (McCutchan et al., 
1968) with 10 to 40 pg of DNA, using vector DNA to 
achieve equimolar concentrations in separate tests. 
The CaHPO,-DNA precipitate was removed 4 to 8 hr 
after addition and the cells were grown in fresh me- 
dium. TPA (tumor promoting agent, phorbol-12-myris- 
tate-13-acetate) was added to a final concentration of 
20 r-&I. Cell differentiation of the F9 line was induced 
by treatment with 1 PLM retinoic acid for at least 4 days. 
Spontaneously growing B-cell lines were cultured from 
EBV-positive peripheral blood lymphocytes. Two 
weeks after isolation of the lymphocytes by centrifuga- 
tion in Ficoll-metrizoate gradients (density 1.077) cy- 
closporin A was added at a concentration of 1 pg/ml to 
suppress T-cell growth, and the medium was ex- 
changed once a week. Within 4 to 6 weeks spontane- 
ous growth of EBV-positive B cell populations was ob- 
served. 
HBsAg reporter system and CAT assay 
The HBsAg reporter system is based on the secre- 
tion of HBsAg (missing pre-S sequences) into the cul- 
ture supernatant and its quantification correlating to 
the tested promoter activity (Marschall et a/., 1989b). 
HBsAg production was assayed in supernatant ali- 
quots by the commercially available, quantitative radio- 
immunoassay for HBsAg (Abbott). Since cell lysis was 
not required, transfection assays could be continu- 
ously monitored over a period of time. For CAT assays, 
the cells were washed in phosphate-buffered saline 
(PBS) 2 days post-transfection and lysed by sonication 
in 100 ~1 of 0.25 11/1Tris-HCI, pH 8.0, on ice. Cell debris 
was removed by centrifugation for 5 min at 500 g. The 
protein concentrations were equilibrated after mea- 
surement of the optical densities at 260 and 280 nm. 
The protein extract (50 ~1) was mixed with a reaction 
mixture containing 100 ~1 of 0.25 1\/1 Tris-HCI (pH 8.0) 
20 ~1 of 4 mM acetyl coenzyme A (Pharmacia-LKB), 
and 10 ~1 of [14C]chloramphenicol (0.25 &i, Amer- 
sham) and incubated for 1 hr at 37°C. Chlorampheni- 
col and its acetylated products were extracted with 
400 PI of ethyl acetate and evaporated in a speed-vac- 
uum centrifuge. Dried samples were resuspended in 
10 ~1 of ethyl acetate and spotted on silica gel thin- 
layer chromatography plates (Merck 5737) in chloro- 
form:methanol (95:5) solvent. The plates were ex- 
posed on hyperfilm-@max (Amersham) for 12 to 24 hr. 
Western blot and immunofluorescence 
For Western blots, bacterial protein extracts were 
prepared from exponentially growing transformed 
fscherichia co/i clones. Protein synthesis was induced 
by addition of 2 mn/r isopropyl-/3-o-thiogalactopyrano- 
side for at least 2 hr. Lysates were prepared in 2Ob 
sodium dodecyl sulfate (SDS) by sonication. Standard 
immunoblotting and modified staining procedures 
were described previously (Marschall et al., 1989a). 
For indirect immunofluorescence, transfected cells (2 
days post-transfection) were fixed in ice-cold acetone 
for 5 min. Human antisera and fluorescein isothiocyan- 
ate-linked goat anti-human antibodies (Medac) were 
applied 1:50 for 1 hr at 37°C. After the cells were 
washed with PBS, the slides were evaluated at a micro- 
scope magnification of 250. 
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Southern blot 
For Southern blots, 10 pg of total cell DNA was di- 
gested with Sstl restriction enzyme and separated in 
1.5% (w/v) agarose gels. The DNA transfer onto nylon 
membranes was achieved by suction through What- 
man filters in 20X SSC buffer (3 IVI NaCI, 0.3 M Na 
citrate) for 8 hr. Crosslinking was done by a 5-min ex- 
posure to ultraviolet light. Hybridization of the blots 
was performed as described in detail by Boehringer 
Mannheim, “DNA Labeling and Detection Kit, 
Nonradioactive.” As BI’LF4-specific probe, a 1 .O-kb 
Sstl fragment was isolated from the Sstl digest of pSVI’. 
The nonradioactive labeling with digoxigenin (Dig- 
dUTP) was again done following the instruction men- 
tioned above. 
RESULTS 
Genome localization and subcloning 
The ORF BI’LF4 is located in the BamHl I’ region of 
the Raji genome, starting with the ATG codon at posi- 
tion 141 15 (paul.sin-sequence, kindly offered by Paul 
Farrell) (Baer et al., 1984; Farrell et al., 1987; Hatfull et 
al., 1988). Sequence analysis identified conserved pro- 
moter motifs, e.g., TATA box, a cryptic CAAT signal 
(position -75), and a perfect AP-1 binding site (position 
-450) (Angel et a/., 1987). As the BamHl I’ fragment is 
partly deleted in the B95-8 standard genome (Fig. 1 A), 
all subclones were constructed using M-ABA strain 
DNA (Polack et a/., 1984). 
In the eucaryotic expression vectors pSVl’and pSCI’, 
the ORF BI’LF4 was expressed under the control of 
heterologous promoters and terminated by the simian 
virus 40 polyadenylation signal. Efficient RNA transport 
was achieved by the insertion of the SV40 splice ac- 
ceptor and donor. In pSCI’, the coding sequence was 
controlled by a strong hybrid promoter (SV40 early en- 
hancer plus HCMV immediate early promoter/en- 
hancer). Two vectors with different promoter/operator 
systems were used for the I’ta protein synthesis in E. 
co/i, pTrcl’(Fig. 1 B) and pUHI’(see Materials and Meth- 
ods). The I’ta promoter was analyzed using the reporter 
plasmids pl’CAT and pl’HBs. 
Vans-Activity and autoregulation 
trans-Regulatory functions of the I’ta product were 
tested in cotransfection assays. Reporter plasmids 
with selected promoters were analyzed for increased 
activity as a consequence of I’ta expression (Fig. 2A). 
No effect was seen on heterologous targets, such 
as the SV40 early promoter/enhancer (pSVCAT) and 
the HCMV immediate early promoter/enhancer 
(pCMVCAT). Using a reporter construction with the 
SV40 early promoter, lacking the 72-bp enhancer re- 
peats (p21CAT not shown), the basal level of expres- 
sion was reduced to where no responsiveness to I’ta 
was detected. Several EBV promoters of different regu- 
latory classes, e.g., immediate early (pZCAT, pRCAT), 
early (pACAT), and latent (pNCAT), were likewise not 
activated. A specific trans-activation, however, was 
shown for two test constructions of the EBV early MS 
promoter (pS1 CAT: 127-bp basic promoter, pSCAT: 
1.4-kb upstream element plus basic promoter) and for 
the I’ta promoter itself (pl’CAT). The strong influence on 
the proximal part of the MS promoter was studied in 
detail under concentration-dependent test conditions 
using the HBsAg (hepatitis B virus surface antigen) re- 
porter system (Fig. 3A). Autoactivation of the I’ta pro- 
moter by its own gene product could be intensified 
with the efficient expression vector pSCI’ (Fig. 2B). 
Cell differentiation and promoter stimulation 
The mouse teratocarcinoma line F9 was used as a 
cell system for inducible differentiation by retinoic acid 
(Umesono et al., 1988). Coactivation of different EBV 
promoters by differentiation-dependent cellular regula- 
tors was studied in the absence of viral proteins. Most 
of the EBV target promoters did not respond to 
changes in the differentiation stage and growth behav- 
ior, while the I’ta promoter and the distal segment of 
the MS promoter were clearly activated in retinoic 
acid-treated cells (Fig. 3B). Induction of other con- 
structs with very low basal activity was likewise not 
detected in independent assays, even after attempts to 
enrich the reporter protein particles by ultracentrifuga- 
tion. 
Two further effects of influencing the activity of the 
I’ta promoter were tested. Since the regulatory up- 
stream sequence contains an AP-1 consensus binding 
site, high promoter activity was assumed to be induced 
by TPA incubation (Lee et al., 1987) or by expression of 
Zta (Farrell et al., 1989; Urier et al., 1989). Our findings 
indicate that both pathways of activation stimulate the 
I’ta promoter to a certain extent (Fig. 2B), but to a level 
much lower than that observed for autostimulation. We 
propose therefore that mainly cellular differentiation 
triggers the synthesis of the I’ta protein, which subse- 
quently accelerates its own expression. 
Expression and nuclear localization 
Using procaryotic in-frame vectors, the ORF BI’LF4 
was expressed as an authentic viral protein without 
heterologous carboxy-terminal fusion (Fig. 4A). Depen- 
dent on reliable promoter/operator systems, the poly- 
peptide was stably expressed in E. co/i in amounts suf- 
ficient for further characterization. We determined a 
molecular weight of 48 kDa, which was in line with the 















FIG. 1. Genome mapping of the I’ta gene (A) and construction of expression and reporter plasmids (B). The structure of three EBV genome 
types is shown in the linearized form, subdivided into BamHl fragments. The ORFs of the Raji strain BamHl I’ fragment are presented in an 
enlarged drawing (boldface arrows). Promoter elements are indicated by bent, horizontal arrows. In the eucaryotic expression vectors pSVI’and 
pSCI’. the enhancer repeats are drawn as open circles (SV40 21 and 72 bp) or rhombs (HCMV 17, 18, 19, and 21 bp). Polyadenylation signals 
and splice acceptors/donors are marked by vertical arrows and angles, respectively. Procaryotic elements of pTrcf’are abbreviated as ori (origin 
of replication), ApR (ampicillin resistance), lac 1’ (repressor allele), and P,, (inducible hybrid promoter). The test constructions for the I’ta 
promoter, pl’HBs and pl’CAT, contain the coding sequences for the hepatitis B virus surface antigen (HBsAg) or chloramphenicol acetyltransfer- 
ase (CAT) as reporters. Restriction enzymes: A, Accl; A’, AU; B, BarnHI; B’, Bglll; E, EcoRI; H, HindIll; H’. Hincll; H’, Hpall; N, Ncol; P, Pstl; S, 
Sall; S’, Sstl; S2, Smal; S3, Stul; T, Taql; X, Xbal 
sequence prediction. High titers of I’ta-specific antibod- 
ies in human sera, derived from patients with naso- 
pharyngeal carcinoma, indicate the relevance of the 
gene product during natural infection. 
Expression of I’ta in transfected eucaryotic cells was 
analyzed by immunofluorescence. A small percentage 
(2-5%) of transfected cells showed a bright, mostly 
nuclear fluorescence when incubated with human an- 
tisera. Most of the positive ceils showed a nuclear 
staining (Fig. 4B). Mock-transfected cells and EBV- 
negative sera (preabsorbed with a mix of E. co/i and 
BJA-B cell extracts, respectively) were used in control 
experiments and did not give positive signals. 
Presence in individual EBV isolates 
We tested the presence of the ORF BI’LF4 on DNA 
level by Southern blot analysis (Fig. 5). Several estab- 
lished EBV-positive and -negative Burkitt lymphoma 
lines were compared to spontaneously growing B cells 
of seven EBV-positive persons. The BI’LF4-specific 
1 .O-kb Sstl fragment, originally subcloned from the M- 
ABA type, was found in all individual isolates in its unal- 
tered molecular size. The Raji and the PSHR-1 strain 
were used as positive controls. Both Sstl recognition 
sequences were conserved in all EBV types tested. As 
expected, no BI’LF4 signal was detected in DNA from 
EBV-negative cells and in the mutant B95-8 strain. 
DISCUSSION 
The most important interpretations of our observa- 
tions are the following: (i) the EBV genome encodes a 
trans-acting factor in the ORF BI’LF4; (ii) this factor has 
strong and specific regulatory effects but can be dis- 
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FIG. 2. CAT assays, showrng the trans-actrvation by the I’ta product (A) and the regulatron of its promoter (6). HeLa cells were transfected with 
20 rg of total DNA. The reporter plasmids contained the following promoters: SV40 early (pSVCAT), HCMV Immediate early (pCMVCAT), EBV 
BMLFl/BSLF2 (pS1 CAT, 127.bp basic promoter; and pSCAT, 1.4.kb promoter/upstream sequence), BZLFl (pZCAT), BI’LF4 (pl’CAT), BRLFl 
(pRCAT). BALF2 (pACAT), and BNLFl (pNCAT). Promoter actrvation was assayed usrng the expression vectors pSVI’. pSCI’, and pCMVZ or by 
TPA inductton. 
pensed in vitro at least in lymphoid cells, where a mod- 
erate lytic cycle of EBV in marmoset-derived B95-8 
cells is observed; (iii) its promoter is regulated by cellu- 
lar factors and by its own gene product; (iv) the I’ta 
activity is not restricted to lymphoid cells and is in- 
fluenced by the differentiation stage of the host cell; (v) 
the gene product is a 48-kDa protein which is trans- 
ported into the nucleus; and (vi) the gene is present in 
individual EBV isolates, indicating its general impor- 
tance in natural infection. 
We characterized a 48-kDa EBV gene product which 
is mapping in the BarnHI I’ region of EBV but is deleted 
in the B95-8 cell-derived EBV genome. Recent tran- 
script analyses proved the affiliation of I’ta to the imme- 
diate early regulatory class. Studies in freshly infected 
or superinfected B-cell lines, in the presence of transla- 
tion inhibitors, delineated that l’ta is an immediate early 
gene because its expression does not depend on prior 
protein synthesis (U. Leser, 1990, Ph. D. thesis, Univer- 
sity of Munich, FRG; U. Leser, manuscript in prepara- 
tion). Parallel to the two other immediate early factors 
of EBV, BZLFl (EBI ; Chevallier-Greco eta/., 1986) (ZE- 
BRA; Countryman et a/., 1987) (Zta; Cox et a/., 1990) 
and BRLFl (R; Hardwick et a/., 1988) (Rta; Cox et al., 
1990), l’ta activates the early antigen level by turning on 
the BMLFl/BSLF2 gene. The promoter of this univer- 
sal, post-transcriptional MS regulator (Buisson er al., 
1989; Kenney et al., 1989a; Kenney et al., 198913) was 
characterized as a target for different pathways follow- 
ing the lytic switch (Marschall et a/., in press). 
Although the regulatory properties of the I’ta product 
are proven, its role in the lytic cascade can obviously 
be substituted. This situation is in line with the regula- 
tion of herpes simplex virus, where the powerful ICPO 
trans-activator is not essential for the viral cycle (San- 
dri-Goldin et al., 1987). In context with the central role 
of nonlymphoid, in particular differentiating epithelial 
cells in the life cycle of EBV (Becker eta/., 1989; Wolf et 
a/., 1984) the responsiveness of the I’ta promoter to 
differentiation-dependent host factors may play a key 
role in the biology of EBV. Although mouse cells, as 
used in our model system, are unlikely to support either 
latent or lytic EBV replication, our results clearly show 
the responsiveness of distinct EBV promoter elements 
to cellular factors with transient activity. Morphological 
change in the differentiating cells was correlated to the 
induction of the I’ta promoter independent from EBV. 
The fact that the gene is deleted in the viral genome 
of the B95-8 line, extensively passaged in nonnatural 
marmoset lymphocytes, suggests selective pressure 
against efficient virus replication for the benefit of the 
host cells. In viva the selective pressure apparently is 
reversed in favor of the most active viruses, as this 
deletion was never found in recently established cell 
lines and only once in a cell culture with an extensive 
history of viral propagation (Shope et al., 1973). 
The finding that complex viruses have alternate, 
partly redundant genes sheds new light on cell type- 
specific regulation. Activation of the I’ta product might 
explain the high efficiency of lytic EBV expression in 
epithelial cells (seen in the tonsils during infectious 
mononucleosis, in the parotid gland of all seroposi- 
tives, and in the hairy leukoplakia lesions of AIDS pa- 
tients). Viruses will frequently not replicate in unre- 
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FIG. 3. Radioimmunoassay data of the HBsAg reporter system 
showing specific %srans-activation in transfected HeLa cells (A) or dif- 
ferentiation dependence in teratocarcinoma F9 cells (B). transActi- 
vation of the EBV MS promoter (pS1 HBs) by I’ta was measured by 
the cotransfection of different concentrations of pSVI’ (1, 0 pg; 2, 10 
pg; 3, 20 pg; 4, 30 pg). The values in row A of panel A refer to 
supernatant samples of the first 2 days and in row B of the following 
2 days post-transfection. 10 ml of the culture supernatant was as- 
sayed in each case. Panel B shows HBsAg reporter expression in F9 
cells, without retinoic acid treatment (row A) or with retinoic acid 
treatment (row B). Each left value (a) reflects the promoter activity of 
the first 2 days and each right value (b) of the following 2 days post- 
transfection. The target promoters used are described in Fig. 2 (1, 
pZHBs; 2, pRHBs; 3, pSHBs; 4, pS1HBs; 5, pl’HBs; 6, pAHBs; 7, 
pNHBs). 
placeable, undifferentiated cells but will replicate in dif- 
ferentiated epithelium, often localized on outer sur- 
faces. Supply of such cells is limited and self- 
renewing. Similar concepts can be seen for papilloma 
viruses. 
An interesting feature of the I’ta gene is the positive 
feedback effect on its own promoter. This is in contrast 
to reports on immediate early genes of herpes simplex 
virus which seem to limit their gene expression by 
down-regulation of their own promoters (O’Hare era/., 
1987). Such an autorepression has not been found so 
far within the EBV system. However, alternative ways 
of positive regulation were detected (moderate respon- 
siveness to TPA, Zta; consensus AP-1 binding site), 
although their relevance in the lytic cycle still awaits 
further experimental data. 
The nucieotide sequence of the l’ta gene was com- 
pared with those of well-characterized viral or cellular 
regulatory genes, such as the coding regions for EBV 
Zta and Rta, for human c-fos and c-jun, for human im- 
munodeficiency virus 1 tat, human adenovirus 4 El A, 
human cytomegalovirus immediate early 1, herpes 
simplex virus 1 ICP 0, pseudorabies virus 180-kDa pro- 
tein, and hepatitis B virus X gene, using GCG software 
A 
B 
FIG. 4. Synthess of I’ta protein in E. co/i (A) and HeLa or COS-1 
cells (B). Western blots with different bacterial extracts (1, pTrc99A; 
2, pTrcl’; 3, pTrcl’ Induced; 4, pUHE24-2; 5, pUHI’; 6, pUHI’induced) 
were incubated with a human serum pool (nasopharyngeal carci- 
noma patients) and stained in alkaline phosphatase procedures. The 
molecular size was determined by comparison with a protein stan- 
dard (Sigma; 116, 97.4, 66, 45, and 29 kDa). lmmunofluorescence 
staining of transfected cells (1 to 3. pSVI’; 4 to 5, pSCI’) with a human 
serum pool shows the nuclear localization of the l’ta protein in adher- 
ent HeLa (1 to 4) and trypsinized COS-1 cells (5). 
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FIG. 5. Southern blot, demonstrating the presence of ORF BI’LF4 in 
different EBV strains. A digoxigenin-labeled BI’LF4-specific probe 
was used to detect a 1 .O-kb Sstl fragment in total DNAs of EBV-posl- 
tive (Rajl, 895-8, P3HR-l), EBV-negative (BJA-B, BL02) B-cell lines, 
and seven individual EBV isolates from spontaneously growing pe- 
npheral B lymphocytes (Gr, Ri. Rf, Md, Mn. Sa, Wg). The 1 .O-kb Sstl 
control, isolated from BI’LF4 in pSVI’, and phage X DNA, digested 
with HindIll. were used as molecular size markers. 
(Devereux, Haeberli and Smithies; Wisconsin). How- 
ever, no stringent homologies, e.g., in DNA binding 
regions or protein complexing domains, were de- 
tected. 
Some interesting questions remain to be answered. 
For example, is the I’ta activity in vivo dependent on the 
cell type? Obviously in lymphocytes, deletion of I’ta 
moderates the EBV phenotype with respect to the lytic 
activity. One might speculate that complementation 
with I’ta might increase the efficiency of the Iytic gene 
expression in 895-8 cells, comparable to the EBV regu- 
lation in the high producer strain P3HR-1. In the P3HR- 
1 strain, an elevated amount of Zta, derived from the 
WZhet DNA (Rooney et al., 1988), constitutively pro- 
motes the lytic cycle. Alternatively I’ta could be a func- 
tion required primarily in nonlymphoid target cells as 
mentioned above. 
In addition to its role in the Iytic infection, one would 
have to consider possible other functions, e.g., in cell 
transformation via interaction with cell proliferation, as 
has been shown for the tax gene of the human T lym- 
photropic virus-l (Leung et a/., 1988). It may also play a 
role in EBV immunology. Cytotoxic T-cell responses 
against immediate early proteins, as studied in detail 
for other herpesvirus systems (Reddehase et a/., 
1989), have been involved in control of EBV infection of 
humans as well (Jilg et al., 1989). 
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